-
2022-500535-36-00
5
Moderately to severely active ulcerative colitis
-
2022-500537-84-00
5
Moderately to severely active ulcerative colitis
-
2022-502043-35-00
5
Advanced Biliary Tract Cancers
-
2024-515603-19-00
4
Localized digestive Neuroendocrine Carcinomas
-
2024-519922-19-00
4
Neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin
-
2025-523766-25-00
5
Ulcerative colitis
-
2023-507010-27-00
5
Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cu
-
2024-510811-32-00
5
acute pneumonia
-
2024-513889-19-00
5
Multiple Myeloma
-
2024-514243-29-01
5
This is a prospective, French, multicenter, open-label, design, strati
-
2024-514633-38-00
5
Crohn’s Disease
-
2024-515362-13-00
10
Philadelphia-negative myeloproliferative neoplasms are frequent and ch
-
2024-515603-19-01
4
Localized digestive Neuroendocrine Carcinomas
-
2024-516167-86-00
5
Patients referred for an isolated or a combined surgical correction of
-
2024-516215-24-00
4
TAkayasu ARteritiS
-
2024-516257-44-00
4
Multiple myeloma
-
2024-516570-30-00
4
Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
-
2024-516796-33-00
4
The medical condition studied in IMMUNO-BOS is Bronchiolitis obliteran
-
2024-517130-17-00
9
FLT3-mutated Acute Myeloid Leukemia
-
2024-518013-25-00
4
Idiopathic Pulmonary Fibrosis
-
2024-518138-10-00
4
Patients with DMMR and/or MSI metastatic colorectal cancer
-
2024-519986-23-00
5
The study will involve adult women and men from 16 French centers who
-
2025-520554-11-00
5
Cardiovascular Disease
-
2025-521090-14-00
4
Patients with relapsed/refractory symptomatic multiple myeloma (MM)